CLAIMS

In the claims:

Claims 1 to 4. (Cancelled)

Claims 5 to 7. (Cancelled)

8. (Currently Amended) A method of ~~modulating~~ **inhibiting** angiogenesis/vascular development in a host **having a condition associated with unwanted angiogenesis**, said method comprising:

systemically administering to said host an effective amount of a Ca2+/calcineurin/NF-ATc ~~modulatory~~ **inhibitory** agent to **inhibit** ~~modulate~~ angiogenesis/vascular development in said host~~, said method comprising~~ **having a condition associated with unwanted angiogenesis**.

9. (Original) The method according to Claim 8, wherein said agent is an NF-ATc antagonist.

10. (Original) The method according to Claim 9, wherein said agent inhibits phosphorylation of NF-ATc.

11. (Original) The method according to Claim 10, wherein said agent inhibits NF-ATc phosphorylation by binding to calcineurin.

Claims 12 to 14. (Cancelled)

15. (Currently Amended) A method of inhibiting tumor growth in a host **having a neoplastic disease condition**, said method comprising:

systemically administering to said host **having a neoplastic disease**

condition an effective amount of a Ca2+/calcineurin/NF-ATc inhibitory agent to inhibit tumor growth in said host.

16. (Original) The method according to Claim 15, wherein said agent is an NF-ATc antagonist.

17. (Original) The method according to Claim 16, wherein said agent inhibits phosphorylation of NF-ATc.

18. (Original) The method according to Claim 16, wherein said agent inhibits NF-ATc phosphorylation by binding to calcineurin.

Claims 19 to 29. (Cancelled)

Claims 30 to 34. (Cancelled)

35. (Previously Presented) The method according to Claim 8, wherein said agent is FK506 or a synthetic mimetic thereof.

36. (Currently Amended) The method according to Claim 8, wherein said agent is ~~**rapamaycin**~~ **rapamycin** or a synthetic mimetic thereof.

37. (Previously Presented) The method according to Claim 8, wherein said agent is a cyclosporin.

38. (Previously Presented) The method according to Claim 37, wherein said cyclosporin is cyclosporin A.

39. (Previously Presented) The method according to Claim 38, wherein said cyclosporin is a synthetic derivative or mimetic of cyclosporin A.

40. (New) The method according to Claim 15, wherein said agent is FK506 or a synthetic mimetic thereof.

41. (Currently Amended) The method according to Claim 15, wherein said agent is ~~rapamaycin~~ **rapamycin** or a synthetic mimetic thereof.

42. (Previously Presented) The method according to Claim 15, wherein said agent is a cyclosporin.

43. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is cyclosporin A.

44. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is a synthetic derivative or mimetic of cyclosporin A.

45. (Cancelled)

46. (Currently Amended) A method of ~~modulating~~ **inhibiting** angiogenesis/vascular development in a host **having a condition associated with unwanted angiogenesis**, said method comprising:

administering to said host an effective amount of a cyclosporin **to inhibit angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis**.

47. (Currently Amended) A method of inhibiting tumor growth in a host **having a neoplastic disease condition**, said method comprising:

administering to said host an effective amount of a cyclosporin **to inhibit tumor growth in said host having a neoplastic disease condition**.